Table 5. Pharmacokinetics of DB829 in vervet monkeys with second stage HAT after the 5^th intramuscular dose.

		Group 1		Group 2		Group 3
Outcome	Units	569F	659M	668M	676F	546M	693F
Tmax	day	0.04	0.04	0.04	0.04	0.04	0.04
Cmax	nmol/L	12000	15000	16000	8900	4200	5900
AUClast †	nmol/L•day	12000	13000	97000	35000	7700	4500
AUC0-∞	nmol/L•day	13000	15000	120000	40000	8300	5300
Cl/F	L/day/kg	0.85	0.76	0.09	0.28	0.67	1.0
t½	day	34	44	130	180	33	42

Group 1 = 5 mg/kg × 5 consecutive days; Group 2 = 5 mg/kg × 5 alternating days; Group 3 = 2.5 mg/kg × 5 consecutive days; F, female; M, male; T_max, time to reach C_max; C_max, maximum concentration; AUC_last, AUC from time 0 to the last measurable concentration; AUC_(0-∞), AUC from 0 to infinite time; Cl/F, apparent clearance; t_½, terminal half-life;

^† = last measurable concentration varied between monkeys (112–490 days).